Fox Run Management L.L.C. Acquires New Holdings in Guardant Health, Inc. $GH

Fox Run Management L.L.C. bought a new position in Guardant Health, Inc. (NASDAQ:GH) in the 3rd quarter, HoldingsChannel reports. The institutional investor bought 9,998 shares of the company’s stock, valued at approximately $625,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Norges Bank bought a new position in shares of Guardant Health in the second quarter valued at approximately $64,136,000. Franklin Resources Inc. grew its stake in Guardant Health by 78.2% in the 2nd quarter. Franklin Resources Inc. now owns 2,319,947 shares of the company’s stock valued at $120,730,000 after buying an additional 1,018,144 shares during the last quarter. Invesco Ltd. raised its holdings in Guardant Health by 27.3% in the 2nd quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock worth $185,184,000 after acquiring an additional 763,834 shares during the period. Jennison Associates LLC acquired a new position in Guardant Health during the 2nd quarter worth $37,233,000. Finally, Nikko Asset Management Americas Inc. boosted its holdings in Guardant Health by 49.6% during the second quarter. Nikko Asset Management Americas Inc. now owns 2,030,428 shares of the company’s stock valued at $105,623,000 after acquiring an additional 673,438 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on GH shares. UBS Group reiterated a “buy” rating and issued a $175.00 price objective on shares of Guardant Health in a research note on Friday, January 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Thursday, January 22nd. Mizuho set a $135.00 price target on Guardant Health in a report on Friday, January 9th. Evercore set a $110.00 price objective on Guardant Health in a research report on Friday, February 20th. Finally, Robert W. Baird started coverage on shares of Guardant Health in a research report on Tuesday, February 17th. They set an “outperform” rating and a $120.00 target price on the stock. Twenty-one investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $122.57.

Insiders Place Their Bets

In other news, Director Medina Manuel Hidalgo sold 1,250 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $105.00, for a total value of $131,250.00. Following the completion of the transaction, the director directly owned 797 shares of the company’s stock, valued at approximately $83,685. This represents a 61.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Amirali Talasaz sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $105.05, for a total value of $10,505,000.00. Following the transaction, the chief executive officer owned 168,223 shares of the company’s stock, valued at $17,671,826.15. This trade represents a 37.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 434,511 shares of company stock valued at $45,580,887 over the last 90 days. Company insiders own 6.10% of the company’s stock.

Guardant Health Trading Down 4.2%

Shares of NASDAQ GH opened at $93.90 on Friday. The business has a fifty day simple moving average of $106.29 and a 200 day simple moving average of $87.51. The firm has a market capitalization of $12.32 billion, a price-to-earnings ratio of -28.37 and a beta of 1.63. Guardant Health, Inc. has a one year low of $34.88 and a one year high of $120.74.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million for the quarter, compared to analysts’ expectations of $269.74 million. During the same quarter in the prior year, the company earned ($0.62) EPS. Guardant Health’s quarterly revenue was up 39.4% on a year-over-year basis. On average, research analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.